These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21051677)

  • 1. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
    Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
    Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
    Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
    J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Capuron L; Ravaud A; Miller AH; Dantzer R
    Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
    Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
    Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
    Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
    J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
    Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
    Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
    Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
    Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings.
    Yoshida K; Alagbe O; Wang X; Woolwine B; Thornbury M; Raison CL; Miller AH
    Neuropsychobiology; 2005; 52(2):55-61. PubMed ID: 15990456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
    Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
    J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
    Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.
    Albrecht K; Droll H; Giesler JM; Nashan D; Meiss F; Reuter K
    Psychooncology; 2013 Sep; 22(9):1972-8. PubMed ID: 23288588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
    Ziefle S; Egberts F; Heinze S; Volkenandt M; Schmid-Wendtner M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Heinz A; Hauschild A; Schaefer M
    J Immunother; 2011 May; 34(4):403-8. PubMed ID: 21499123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.
    Bannink M; Fekkes D; Van Gool AR; Kruit WH; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
    Neuropsychobiology; 2007; 55(3-4):225-31. PubMed ID: 17873497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to manage melanoma in a psoriatic patient.
    Papadavid E; Psyrri A; Pectasides D; Katoulis A; Balamoti E; Dalamaga M; Stavrianeas N
    Dermatology; 2008; 216(3):277-8. PubMed ID: 18196939
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.